The Biomarkers consortium: Practice and pitfalls of open-source precompetitive collaboration

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 5, 2010, Pages 539-542

  Wagner, J A ^a   Prince, M ^b   Wright, E C ^c   Ennis, M M ^d   Kochan, J ^e   Nunez, D J R ^f   Schneider, B ^g   Wang, M D ^b   Chen, Y ^a   Ghosh, S ^h   Musser, B J ^a   Vassileva, M T ⁱ  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d IQVIA   (United States)

^e HOFFMANN LA ROCHE INC   (United States)

^f GLAXOSMITHKLINE   (United States)

^g CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^h NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; TRIACYLGLYCEROL;

CREATININE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MEDICAL RESEARCH; METABOLIC DISORDER; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NON PROFIT ORGANIZATION; NOTE; PATIENT CARE; PREDICTOR VARIABLE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BIOLOGICAL MARKERS; COOPERATIVE BEHAVIOR; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG INDUSTRY; ECONOMIC COMPETITION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77951427198     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.227     Document Type: Note

References (10)

1. Kola, I. The state of innovation in drug development. Clin. Pharmacol Ther. 83, 227-230 (2008).
2. Kaitin, K.I. Obstacles and opportunities in new drug development. Clin. Pharmacol Ther. 83, 210-212 (2008).
3. Weber, S. The Success of Open Source (Harvard University Press, Cambridge, MA, 2004).
4. Melese, T., Lin, S.M., Chang, J.L. & Cohen, N.H. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat. Med. 15, 502-507 (2009).
5. Friend, S. & Schadt, E. Something wiki this way comes [interview by Bryn Nelson]. Nature 458, 13 (2009).
6. Altar, C.A. The Biomarkers Consortium: on the critical path of drug discovery. Clin. Pharmacol Ther. 83, 361-364 (2008).
7. Wagner, J.A., Williams, S.A. & Webster, C.J. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin. Pharmacol Ther. 81, 104-107 (2007).
8. Wagner, J.A. et al. Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors. Clin. Pharmacol Ther. 86, 619-625 (2009).
9. American Diabetes Association. Abstracts of the 69th Scientific Session, New Orleans, LA, 5-9 June 2009
10. Hughes, B. Novel consortium to address shortfall in innovative medicines for psychiatric disorders. Nat. Rev. Drug Discovery 8, 523-524 (2009).